Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

81. Budesonide once versus twice-daily administration: meta-analysis

Budesonide once versus twice-daily administration: meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

82. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study

An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

83. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. (PubMed)

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Although inhaled glucocorticosteroids are recommended for persistent asthma, their long-term effect on recent onset, mild, persistent asthma has yet to be established.We did a randomised, double-blind clinical trial in 7241 patients in 32 countries to assess the effects of budesonide in patients who had had mild persistent asthma for less than 2 years and who had not had previous regular treatment (...) with glucocorticosteroids. Patients aged 5-66 years received either budesonide or placebo once daily for 3 years in addition to their usual asthma medications. The daily budesonide dose was 400 microg, or 200 microg for children younger than 11 years. The primary outcome was time to first severe asthma-related event, and analysis was by intention to treat.198 of 3568 patients on placebo and 117 of 3597 on budesonide had at least one severe asthma exacerbation; hazard ratio 0.56 (95% CI 0.45-0.71, p<0.0001). Patients

2003 Lancet

84. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma

Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

85. Fluticasone versus beclomethasone or budesonide for chronic asthma. (PubMed)

Fluticasone versus beclomethasone or budesonide for chronic asthma. Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma, Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays.To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma.We searched the Cochrane Airways Group Trial Register (1999) and reference lists of articles. We (...) contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999).Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.One reviewer extracted data. Quantitative analyses where undertaken using Review Manager 4.0.3 with Metaview 3.1.42 studies (>10,000

2002 Cochrane

86. Systematic review: the effectiveness of budesonide therapy for Crohn's disease

Systematic review: the effectiveness of budesonide therapy for Crohn's disease Systematic review: the effectiveness of budesonide therapy for Crohn's disease Systematic review: the effectiveness of budesonide therapy for Crohn's disease Kane S V, Schoenfeld P, Sandborn W J, Tremaine W, Hofer T, Feagan B G Authors' objectives To assess the effectiveness and safety of budesonide in comparison with corticosteroids, 5-aminosalicylic acid (5-ASA) or placebo, for inducing remission of active Crohn's (...) disease and for maintaining remission. Searching MEDLINE and EMBASE were searched from 1980 to 2001 for articles in any language. The search terms used were 'budesonide', 'Crohn disease', 'therapy', 'clinical trial' and 'randomized (pt)'. In addition, reference lists and conference proceedings of the American Gastroenterological Association and the American College of Gastroenterology were handsearched. Researchers and drug companies were contacted for unpublished trials. Study selection Study designs

2002 DARE.

87. Budesonide at different doses for chronic asthma. (PubMed)

Budesonide at different doses for chronic asthma. Inhaled budesonide (BUD) is available in a range of doses for treating chronic asthma.To quantitatively assess the efficacy and safety of budesonide at different doses in order to establish whether a clinically significant dose response profile exists.A search was carried out for Controlled and Randomised Clinical Trials (RCTs) using the Cochrane Airways Group trial register, correspondence with trial authors and the manufacturer.Randomised (...) trials in children and adults comparing one dose of budesonide to a second dose in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.One reviewer extracted data; authors were contacted to clarify missing information. Quantitative analyses where undertaken using Review Manager.24 studies were selected for inclusion in the review (3907 subjects). In non-oral steroid treated, mild to moderately severe asthma no clinically worthwhile

2001 Cochrane

88. Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study

Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Andersson F, Stahl E, Barnes P J, Lofdahl C G, O'Byrne P M, Pauwels R A, Postma D S, Tattersfield A E, Ullman A Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four treatments for patients with persistent symptoms of asthma were examined: low-dose budesonide (total daily dose 200 microg) plus placebo; low-dose budesonide plus formoterol (total daily dose 24 microg); moderate-dose budesonide (total daily dose 800 microg) plus placebo

2001 NHS Economic Evaluation Database.

89. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice

Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Andersson F, Kjellman M, Forsberg G, Moller C, Arheden L Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two maintenance therapies for the management of childhood asthma were compared: budesonide and sodium cromoglycate, both recommended strategies in Sweden. Type of intervention Treatment. Economic study type

2001 NHS Economic Evaluation Database.

90. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. (PubMed)

Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. Antiinflammatory therapies, such as inhaled corticosteroids or nedocromil, are recommended for children with asthma, although there is limited information on their long-term use.We randomly assigned 1041 children from 5 through 12 years of age with mild-to-moderate asthma to receive 200 microg of budesonide (311 children), 8 mg of nedocromil (312 children), or placebo (...) (418 children) twice daily. We treated the participants for four to six years. All children used albuterol for asthma symptoms.There was no significant difference between either treatment and placebo in the primary outcome, the degree of change in the forced expiratory volume in one second (FEV1, expressed as a percentage of the predicted value) after the administration of a bronchodilator. As compared with the children assigned to placebo, the children assigned to receive budesonide had

2000 NEJM

91. Budesonide in the treatment of Crohn's disease: a meta-analysis

Budesonide in the treatment of Crohn's disease: a meta-analysis Budesonide in the treatment of Crohn's disease: a meta-analysis Budesonide in the treatment of Crohn's disease: a meta-analysis Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L Authors' objectives To perform a meta-analysis to assess the effectiveness and safety of oral budesonide for inducing remission in active Crohn's disease and for preventing relapse in Crohn's disease with medically- or surgically-induced remission (...) . Searching MEDLINE (from initiation to date of search) was searched using the following MeSH terms: 'budesonide' and 'Crohn' or 'inflammatory bowel disease'. A manual search of review articles and proceedings from major gastrointestinal meetings (1993-1999) was also performed, and the bibliographies of retrieved articles searched. Only results fully reported in journal articles were included. No language restrictions were reported. Study selection Study designs of evaluations included in the review

2000 DARE.

92. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily (...) and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback B, Jenkins C, Price M J, Thwaites R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Salmeterol/fluticasone propionate combination

2000 NHS Economic Evaluation Database.

93. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis

Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Stahl E, van Rompay W, Wang E C, Thomson D M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Budesonide aqueous nasal spray and fluticasone propionate allergic spray in the treatment of perennial allergic rhinitis (PAR). Type of intervention Treatment. Economic study type Cost

2000 NHS Economic Evaluation Database.

94. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis

A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis Keith P K, Haddon J, Birch S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intranasal budesonide for seasonal allergic rhinitis. Type of intervention Treatment. Economic study type Cost-benefit analysis. Study population Patients suffering from seasonal allergic rhinitis. Setting Community. The study was carried out in Canada. Dates to which data relate

2000 NHS Economic Evaluation Database.

95. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. (PubMed)

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Although patients with chronic obstructive pulmonary disease (COPD) should stop smoking, some do not. In a double-blind, placebo-controlled study, we evaluated the effect of the inhaled glucocorticoid budesonide in patients with mild COPD who continued smoking. After a six-month run-in period, we (...) randomly assigned 1277 subjects (mean age, 52 years; mean forced expiratory volume in one second [FEV1], 77 percent of the predicted value; 73 percent men) to twice-daily treatment with 400 microg of budesonide or placebo, inhaled from a dry-powder inhaler, for three years.Of the 1277 subjects, 912 (71 percent) completed the study. Among these subjects, the median decline in the FEV1 after the use of a bronchodilator over the three-year period was 140 ml in the budesonide group and 180 ml

1999 NEJM

96. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. (PubMed)

Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. Relapses of acute asthma following emergency department (ED) discharge can be reduced with systemic corticosteroid treatment. However, whether inhaled corticosteroids (ICSs) provide additional benefit is not known. Objective To determine whether the addition of ICSs to oral corticosteroid treatment would reduce relapses in patients (...) course of oral prednisone (50 mg/d) for 7 days. In a double-blind fashion, patients were randomly assigned to 1600 microg/d of inhaled budesonide (n = 94) or identical placebo (n = 94) for 21 days.Incidence of relapse, defined as an unscheduled visit for worsening asthma symptoms, in budesonide vs placebo groups. Secondary outcomes included response to the Asthma Quality of Life Questionnaire, beta2-agonist use, symptom score, global asthma improvement assessment, and pulmonary function.Five patients

1999 JAMA

97. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. (PubMed)

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Little is known about the long-term efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). We investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD.We used a parallel-group, randomised, double-blind, placebo-controlled design (...) in a singlecentre study, nested in a continuing epidemiological survey (the Copenhagen City Heart Study). Inclusion criteria were as follows: no asthma; a ratio of forced expiratory volume in 1 s (FEV1) and vital capacity of 0.7 or less; FEV1 which showed no response (<15% change) to 1 mg inhaled terbutaline or prednisolone 37.5 mg orally once daily for 10 days. 290 patients were randomly assigned budesonide, 800 microg plus 400 microg daily for 6 months followed by 400 microg twice daily for 30 months

1999 Lancet

98. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children

The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children Barnes N C, Thwaites R M, Price M J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies were the use of fluticasone propionate (FP) and budesonide (Bud) in the treatment of patients suffering from asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of adult

Full Text available with Trip Pro

1999 NHS Economic Evaluation Database.

99. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. (PubMed)

Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. The effectiveness of glucocorticoids for patients with croup is well established but it remains uncertain which glucocorticoid regimen is most effective.To determine the effectiveness of 3 glucocorticoid regimens in patients with croup.Randomized controlled trial with parallel design.Emergency departments of 2 Canadian pediatric tertiary care hospitals.Children with a clinical syndrome consistent (...) with croup, aged 3 months to 5 years, with a croup score of 2 or greater following at least 15 minutes of mist therapy.Oral dexamethasone, 0.6 mg/kg, and nebulized placebo; oral placebo and nebulized budesonide, 2 mg; or oral dexamethasone, 0.6 mg/kg, and nebulized budesonide, 2 mg.Westley croup score (primary outcome), hospital admission rates, time spent in the emergency department, return visits to the emergency department, or ongoing symptoms at 1 week.The mean change in the croup score from baseline

1998 JAMA

100. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. (PubMed)

A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. In children with croup, treatment with nebulized budesonide decreases symptoms, but it is uncertain how budesonide compares with dexamethasone, the conventional therapy for croup, and whether either reduces the rate of hospitalization.We performed a double-blind, randomized trial involving 144 children with moderately severe croup. The children were treated with racepinephrine (...) and a single dose of 4 mg of nebulized budesonide (48 children), 0.6 mg of intramuscular dexamethasone per kilogram of body weight (47 children), or placebo (49 children). The children were assessed before treatment and then hourly for five hours after treatment. Physicians who were unaware of the treatment assignments determined the children's need for further treatment and hospitalization.The characteristics of the groups were similar at base line, including the types of viruses identified, the types

1998 NEJM